MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

Search

Alkermes PLC

Closed

SectorHealthcare

30.47 1.67

Overview

Share price change

24h

Current

Min

29.59

Max

30.88

Key metrics

By Trading Economics

Income

-124M

22M

Sales

-123M

307M

P/E

Sector Avg

13.723

39.564

EPS

0.291

Profit margin

7.329

Employees

1,800

EBITDA

-168M

14M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+31.89% upside

Dividends

By Dow Jones

Next Earnings

23 Jul 2025

Market Stats

By TradingEconomics

Market Cap

-1B

4.8B

Previous open

28.8

Previous close

30.47

News Sentiment

By Acuity

50%

50%

168 / 376 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Alkermes PLC Chart

Past performance is not a reliable indicator of future results.

Related News

10 Jul 2025, 21:42 UTC

Acquisitions, Mergers, Takeovers

Justice Department Won't Seek Injunction for T-Mobile Acquisition of U.S. Cellular

10 Jul 2025, 17:06 UTC

Acquisitions, Mergers, Takeovers

Portugal Begins Process to Sell Stake in National Carrier -- Update

10 Jul 2025, 17:00 UTC

Major Market Movers

K Wave Media Shares Drop After Convertible Note Agreement With Anson Funds

10 Jul 2025, 16:31 UTC

Acquisitions, Mergers, Takeovers

Blackstone Makes $664 Million Counteroffer for Warehouse REIT Amid Bidding War -- 2nd Update

10 Jul 2025, 23:47 UTC

Market Talk

Gold Edges Higher Amid Lingering Global Trade Tensions -- Market Talk

10 Jul 2025, 23:40 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

10 Jul 2025, 22:36 UTC

Market Talk

Tourism Holdings' Profit Warning Less Concerning Than Others -- Market Talk

10 Jul 2025, 22:23 UTC

Market Talk

New Law Creates Winners and Losers Among Renewable-Energy Projects -- Market Talk

10 Jul 2025, 20:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

10 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 Jul 2025, 20:00 UTC

Acquisitions, Mergers, Takeovers

Toyota Tsusho America Completes Acquisition of Radius Recycling

10 Jul 2025, 19:56 UTC

Market Talk

Gold Rises on Inflation Concerns -- Market Talk

10 Jul 2025, 19:33 UTC

Market Talk

Oil Snaps Winning Streak As Oversupply Concerns Return -- Market Talk

10 Jul 2025, 19:21 UTC

Market Talk

U.S. Natural Gas Rebound on Benign Storage Build -- Market Talk

10 Jul 2025, 18:46 UTC

Market Talk

Mexican Industrial Production Seen as Mixed in May -- Market Talk

10 Jul 2025, 18:15 UTC

Market Talk

Brazil's Bullish Outlook Expected to Survive Trump Tariffs -- Market Talk

10 Jul 2025, 18:03 UTC

Market Talk
Earnings

Travel Agency Investors Cautiously Optimistic After Delta Report -- Market Talk

10 Jul 2025, 17:57 UTC

Market Talk

US Labor Shortage Could Weigh on Business, Economic Growth -- Market Talk

10 Jul 2025, 17:34 UTC

Earnings
Acquisitions, Mergers, Takeovers

Conagra Falls While Simply Good Foods Adapts. What's Eating Food Companies. -- Barrons.com

10 Jul 2025, 17:34 UTC

Market Talk

Canada Vows Fight Over Trump's Copper Tariffs -- Market Talk

10 Jul 2025, 17:20 UTC

Market Talk

Copper Climbs as Futures Wrangle With Trump Tariff -- Market Talk

10 Jul 2025, 17:20 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

10 Jul 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 Jul 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10 Jul 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10 Jul 2025, 16:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 Jul 2025, 16:02 UTC

Market Talk

Global Equities Roundup: Market Talk

10 Jul 2025, 16:02 UTC

Market Talk

Embraer Expected to Bear Brunt of U.S. Tariffs on Brazil -- Market Talk

10 Jul 2025, 16:01 UTC

Acquisitions, Mergers, Takeovers

Investor AB: Advanced Instruments' Acquisition of Nova Biomedical Completed

10 Jul 2025, 15:41 UTC

Market Talk

U.S. Natural Gas Storage Surplus Holds Steady -- Market Talk

Peer Comparison

Price change

Alkermes PLC Forecast

Price Target

By TipRanks

31.89% upside

12 Months Forecast

Average 39.54 USD  31.89%

High 46 USD

Low 30 USD

Based on 13 Wall Street analysts offering 12 month price targets forAlkermes PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

9

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

27.95 / 30.91Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

168 / 376 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.